Clinical reviews

NEOADJUVANT AND ADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC OR GASTRO OESOPHAGEAL CANCER (KEYNOTE-585): AN INTERIM ANALYSIS OF THE MULTICENTRE, DOUBLE-BLIND, RANDOMISED PHASE 3 STUDY

Kohei Shitara, Sun Young Rha, Lucjan S Wyrwicz, Takashi Oshima, Nina Karaseva, Mikhail Osipov, Hisateru Yasui, Hiroshi Yabusaki, Sergey Afanasyev, Young-Kyu Park, Salah-Eddin Al-Batran, Takaki Yoshikawa, Patricio Yanez, Maria Di Bartolomeo, Sara Lonardi,

PDF202313 pages537 KB

The study assesses the antitumor activity of the combination treatment in a multicentre, randomised, placebo-controlled, double-blind phase 3 trial conducted across 143 medical centres in 24 countries. It includes patients aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma. The findings aim to provide insights into the effectiveness of this treatment approach in improving patient outcomes.

Ask this resource

Answers use this document only.

Your first question is free.

More like this

Resources from the same specialty and type. Curated links will replace these when added.